High-affinity, non-nucleotide-derived competitive antagonists of platelet P2Y12 receptors

Journal of Medicinal Chemistry

Volumn 52, Issue 12, 2009, Pages 3784-3793

  Baqi, Younis ^a   Atzler, Kerstin ^a   Köse, Meryem ^a   Glänzel, Markus ^b,c   Müller, Christa E ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c ELSEVIER MASSON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 AMINO 2 SULFO 4 ANILINOANTHRAQUINONE DERIVATIVE; 1 AMINO 2 SULFOANTHRAQUINONE DERIVATIVE; 1 AMINO 4 (4 PHENYLAMINO 3 CARBOXYPHENYLAMINO) 9,10 DIOXO 9,10 DIHYDROANTHRACENE 2 SULFONATE; 1 AMINO 4 (4 PHENYLAMINO 3 SULFOPHENYLAMINO) 9,10 DIOXO 9,10 DIHYDROANTHRACENE 2 SULFONATE; 1 AMINO 4 BROMOANTHRAQUINONE DERIVATIVE; 2 PROPYLTHIOADENOSINE 5' ADENYLIC ACID (1,1 DICHLORO 1 PHOSPHONOMETHYL 1 PHOSPHONYL)ANHYDRIDE; ANTHRAQUINONE DERIVATIVE; CIBACRON BLUE F3GA; COPPER; PBS 0413; PBS 0702; PBS 0739; PURINERGIC P2Y12 RECEPTOR; RADIOLIGAND; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MICROWAVE IRRADIATION; REACTION ANALYSIS; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION;

ANTHRAQUINONES; BINDING, COMPETITIVE; HUMANS; MOLECULAR STRUCTURE; RADIOLIGAND ASSAY; RECEPTORS, PURINERGIC P2; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 67549114979     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9003297     Document Type: Article

References (63)

1. (a) Guile, S. D.; Ince, F.; Ingall, A. H.; Kindon, N. D.; Meghani, P.; Mortimore, M. P. The medicinal chemistry of the P2 receptor family. Prog. Med. Chem. 2001, 38, 115-187.
2. (b) Lambrecht, G.; Braun, K.; Damer, M.; Ganso, M.; Hildebrandt, C.; Ullmann, H.; Kassack, M. U.; Nickel, P. Structure-activity relationships of suramin and pyridoxal-5′-phosphate derivatives as P2 receptor antagonists. Curr. Pharm. Des. 2002, 8, 2371-2399. (Pubitemid 35339325)
3. 3 adenosine receptors. Curr. Top. Med. Chem. 2004, 4, 855-862.
4. (a) Khakh, B. S.; Burnstock, G.; Kennedy, C.; King, B. F.; North, R. A.; Séguéla, P.; Voigt, M.; Humphrey, P. P. International Union of Pharmacology. XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits. Pharmacol. Rev. 2001, 53, 107-118. (Pubitemid 32173110)
5. (b) Abbracchio, M. P.; Burnstock, G.; Boeynaems, J. M.; Barnard, E. M.; Boyer, J. L.; Kennedy, C.; Knight, G. E.; Fumagalli, M.; Gachet, C.; Jacobson, K. A.; Weisman, G. A. International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol. Rev. 2006, 58, 281-341. (Pubitemid 44394905)
6. (c) Brunschweiger, A.; Müller, C. E. P2 receptors activated by uracil nucleotides - an update. Curr. Med. Chem. 2006, 13, 289-312.
7. (d) Müller, C. E. P2-pyrimidinergic receptors and their ligands. Curr. Pharm. Des. 2002, 8, 2353-2369. (Pubitemid 35331541)
8. Gachet, C. Regulation of platelet functions by P2 receptors. Annu. Rev. Pharmacol. Toxicol. 2006, 46, 277-300. (Pubitemid 43271191)
9. (a) Léon, C.; Vial, C.; Gachet, C.; Ohlmann, P.; Hechler, B.; Cazenave, J. P.; Lecchi, A.; Cattaneo, M. The P2Y1 receptor is normal in a patient presenting a severe deficiency of ADP-induced platelet aggregation. Thromb. Haemostasis 1999, 81, 775-781.
10. (b) Cattaneo, M.; Gachet, C. ADP receptors and clinical bleeding disorders. Arterioscler., Thromb., Vasc. Biol. 1999, 19, 2281-2285. (Pubitemid 29477827)
11. Ten Boekel, E.; Bartels, P. Abnormally short activated partial thromboplastin times are related to elevated plasma levels of TAT, F1 + 2, D-Dimer and FVIII:C. Pathophysiol. Haemostasis Thromb. 2002, 32, 137-142. (Pubitemid 37490505)
12. 12 receptors. Bioorg. Med. Chem. Lett. 2005, 15, 5450-5452.
13. Barnard, E. A.; Simon, J. An elusive receptor is finally caught: P2Y(12′), an important drug target in platelets. Trends Pharmacol. Sci. 2001, 22, 388-391. (Pubitemid 32718623)
14. (a) Hollopeter, G.; Jantzen, H. M.; Vincent, D.; Li, G.; England, L.; Ramakrishnan, V.; Yang, R. B. P.; Nurden, A.; Julius, D.; Conley, P. B. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001, 409, 202-207. (Pubitemid 32144286)
15. (b) Zhang, F. L.; Luo, L.; Gustafson, E.; Lachowicz, J.; Smith, M.; Qiao, X.; Liu, Y.-H.; Chen, G.; Pramanik, B.; Laz, T. M.; Palmer, K.; Bayne, M.; Monsma, F. J., Jr. ADP is the cognate ligand for the orphan G protein-coupled receptor SP1999. J. Biol. Chem. 2001, 276, 8608-8615. (Pubitemid 37385678)
16. 1 receptor. Mol. Pharmacol. 2001, 60, 432-439.
17. (a) Savi, P.; Pereillo, J. M.; Uzabiaga, M. F.; Combalbert, J.; Picard, C.; Maffrand, J. P.; Pascal, M.; Herbert, J. M.; Identification and biological activity of the active metabolite of clopidogrel. Thromb. Haemostasis 2000, 84, 891-896. (Pubitemid 30946954)
18. (b) Sugidachi, A.; Asai, F.; Ogawa, T.; Inoue, T.; Koike, H. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br. J. Pharmacol. 2000, 129, 1439-1446. (Pubitemid 30175717)
19. (a) Ingall, A. H.; Dixon, J.; Bailey, A.; Coombs, M. E.; Cox, D.; McInally, J. I.; Hunt, S. F.; Kindon, N. D.; Teobald, B. J.; Willis, P. A.; Humphries, R. G.; Leff, P.; Clegg, J. A.; Smith, J. A.; Tomlinson, W. Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy. J. Med. Chem. 1999, 42, 213-220. (Pubitemid 29069856)
20. (b) Boeynaems, J. M.; van Giezen, H.; Savi, P.; Herbert, J. M. P2Y receptor antagonists in thrombosis. Curr. Opin. Investig. Drugs. 2005, 6, 275-282.
21. 12 antagonists. Semin. Thromb. Hemostasis 2005, 31, 195-204.
22. (a) Douglass, J. G.; Patel, R. I.; Yerxa, B. R.; Shaver, S. R.; Watson, P. S.; Bednarski, K.; Plourde, R.; Redick, C. C.; Brubaker, K.; Jones, A. C.; Boyer, J. L. Lipophilic modifications to dinucleoside polyphosphates and nucleotides that confer antagonist properties at the platelet P2Y12 receptor. J. Med. Chem. 2008, 51, 1007-1025. (Pubitemid 351304709)
23. 12 ADP-receptor antagonist, INS50589. Platelets 2007, 18, 346-356.
24. 12 ADP receptor antagonist, INS50589. J. Thromb. Haemostasis 2005, 3 (1), P2206. http://www.inspirepharm.com/pubs05.html.
25. Inspire Pharmaceuticals, Inc. (ISPH) Terminates Mid-Stage Trial; Cites Bleeding Complications; Aug 8, 2006; http://www.biospace.com/news-story.aspx? NewsEntityId)26661.
26. Cristalli, G.; Podda, G. M.; Costanz, S.; Lambertucci, C.; Lecchi, A.; Vittori, S.; Volpini, R.; Zighetti, M. L.; Cattaneo, M. Effects of 5′- phosphate derivatives of 2-hexynyl adenosine and 2-phenylethynyl adenosine on responses of human platelets mediated by P2Y receptors. J. Med. Chem. 2005, 48, 2763-2766. (Pubitemid 40552908)
27. (a) Tantry, U. S.; Bliden, K. P.; Gurberl, P. A. AZD6140. Expert Opin. Invest. Drugs. 2007, 16, 225-229.
28. 12 antagonists. Semin. Thromb. Hemostasis. 2005, 31, 195-204.
29. 12 receptor antagonist for the prevention of thrombosis. Bioorg. Med. Chem. Lett. 2007, 17, 6013-6018.
30. (a) Serebruany, V. L.; Stebbing, J.; Atar, D. Dyspnoea after antiplatelet agents: the AZD6140 controversy. Int. J. Clin. Pract. 2007, 61, 529-533. (Pubitemid 46271268)
31. (b) Weitz, J. I.; Hirsh, J.; Samama, M. M. New antithrombotic drugs. Chest 2008, 133, 234S-256S.
32. 12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (II): pharmacodynamic and pharmacokinetic characterization. Thromb Res. 2008, 4, 533-540.
33. 12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (I): in vitro effects on platelets. Thromb Res. 2008, 4, 523-532.
34. 12 adenosine diphosphate receptor antagonist that inhibits platelet aggregation and thrombus formation in rat and dog models. Thromb. Haemostasis. 2007, 5, 847-855.
35. Burnstock, G. Introduction: P2 receptors. Curr. Top. Med. Chem. 2004, 4, 793-803.
36. Tuluc, F.; Bültmann, R.; Glänzel, M.; Frahm, A. W.; Starke, K. P2-receptor antagonists: IV. Blockade of P2-receptor subtypes and ecto-nucleotidases by compounds related to reactive blue 2. Naunyn- Schmiedeberg's Arch. Pharmacol. 1998, 357, 111-120. (Pubitemid 28085510)
37. Kulick, M. B.; von Kügelgen, I. P2Y-receptors mediating an inhibition of the evoked entry of calcium through N-type calcium channels at neuronal processes. J. Pharmacol. Exp. Ther. 2002, 303, 520-526. (Pubitemid 35231221)
38. (a) Glänzel, M.; Bültmann, R.; Starke, K.; Frahm, A. W. Constitutional isomers of reactive blue 2sselective P2Y-receptor antagonists. Eur. J. Med. Chem. 2003, 38, 303-312. (Pubitemid 36349673)
39. (b) Glänzel, M.; Bültmann, R.; Starke, K.; Frahm, A. W. Structure-activity relationships of novel P2-receptor antagonists structurally related to reactive blue 2. Eur. J. Med. Chem. 2005, 40, 1262-1276. (Pubitemid 41618267)
40. Atzler, K. J. G-Protein-gekoppelte Rezeptoren als Arzneistoff-Targets: In-Vitro-Charakterisierung neuer Liganden und Untersuchung der Wirkstoff-Rezeptor-Interaktion (G protein-coupled receptors as drug targets: in vitro characterization of new ligands and investigation of drug-receptor interaction). Ph.D. Thesis. University of Bonn: Bonn, Germany, 2006.
41. 12 receptor regulates microglial activation by extracellular nucleotides. Nat. Neurosci. 2006, 9, 1512-1519.
42. (a) Baqi, Y.; Weyler, S.; Iqbal, J.; Zimmermann, H.; Müller, C. E. Structure-activity relationships of anthraquinone derivatives derived from bromaminic acid as inhibitors of ectonucleoside triphosphate diphosphohydrolases (E-NTPDases). Purinergic Signalling 2009, 5, 91-106.
43. 2 receptor antagonists. Bioorg. Med. Chem. Lett. 2008, 18, 223-227.
44. Baqi, Y.; Mü ller, C. E. Rapid and efficient microwave-assisted copper(0)-catalyzed Ullmann coupling reaction: general access to anilinoanthraquinone derivatives. Org. Lett. 2007, 9, 1271-1274.
45. Schumacher, B.; Scholle, S.; Hölzl, J.; Khudeir, N.; Hess, S.; Müller, C. E. Lignans isolated from valerian: identification and characterization of a new olivil derivative with partial agonistic activity at A1 adenosine receptors. J. Nat. Prod. 2002, 65, 1479-1485. (Pubitemid 35239637)
46. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65, 55-63. (Pubitemid 14203433)
47. 12 receptor antagonists, PCT Int. Appl. WO 2008107211 A2, 2008, 111 pp.
48. 12-receptor. Purinergic Signalling 2008, 4, S20.
49. Colourants for Food Contact Plastics: Aspects of Product Safety; Eurocolour, Ecological and Toxicological Association of Dyes and Organic Pigments Manufacturers (ETAD) Verband der Mineralfarbenindustrie (VdMi), 2002; Chapter 4.21, Anthraquinone pigments, p 49; available from www.cefic.be/files/ Publications/FDL-en.pdf.
50. 2 receptor, on airway obstruction in guinea pigs. Br. J. Pharmacol. 2008, 153, 669-675.
51. (a) Ernster, L.; Dallner, G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim. Biophys. Acta 1995, 1271, 195-204.
52. (b) Dutton, P. L.; Ohnishi, T.; Darrouzet, E.; Leonard, M. A.; Sharp, R. E.; Cibney, B. R.; Daldal, F.; Moser, C. C. Coenzyme Q oxidation reduction reactions in mitochondrial electron transport. In Coenzyme Q: Molecular Mechanisms in Health and Disease; Kagan, V. E., Quinn , P. J., Eds.; CRC Press: Boca Raton, FL, 2000; Chapter 4, pp 65-82.
53. (a) Shindo, Y.; Witt, E.; Han, D.; Epstein, W.; Packer, L. Enzymic and non-enzymic antioxidants in epidermis and dermis of human skin. J. Invest. Dermatol. 1994, 102, 122-124. (Pubitemid 24039575)
54. (b) Aberg, F.; Appelkvist, E. L.; Dallner, G.; Ernster, L. Distribution and redox state of ubiquinones in rat and human tissues. Arch. Biochem. Biophys. 1992, 295, 230-234.
55. Ebadi, M.; Govitrapong, P.; Sharma, S.; Muralikrishnan, D.; Shavali, S.; Pellett, L.; Schafer, R.; Albano, C.; Eken, J. Ubiquinone (coenzyme Q10) and mitochondria in oxidative stress of Parkinson's disease. Biol. Signals Recept. 2001, 10, 224-253.
56. Teng, C. M.; Lin, C. H.; Lin, C. N.; Chung, M. I.; Huang, T. F.; Frangulin, B. An antagonist of collagen-induced platelet aggregation and adhesion, isolated from Rhamnus formosana. Thromb. Haemostasis 1993, 70, 1014-1018. (Pubitemid 24008817)
57. Pearson, J. C.; Burton, S. J.; Lowe, C. R. Affinity precipitation of lactate dehydrogenase with a triazine dye derivative: selective precipitation of rabbit muscle lactate dehydrogenase with a procion blue H-B analog. Anal. Biochem. 1986, 158, 382-389. (Pubitemid 17200628)
58. 2 receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling. J. Med. Chem. 2009, 52, 2762-2775.
59. (b) Iqbal, J.; Jirovsky, D.; Lee, S. Y.; Zimmermann, H.; Müller, C. E. Capillary electrophoresis-based nanoscale assays for monitoring ecto-5′-nucleotidase activity and inhibition in preparations of recombinant enzyme and melanoma cell membranes. Anal. Biochem. 2008, 373, 129-140. (Pubitemid 350251331)
60. (c) Brunschweiger, A.; Iqbal, J.; Umbach, F.; Scheiff, A. B.; Munkonda, M. N.; Sévigny, J.; Knowles, A. F.; Müller, C. E. Selective nucleoside triphosphate diphosphohydrolase-2 (NTPDase2) inhibitors: nucleotide mimetics derived from uridine-5′-carboxamide. J. Med. Chem. 2008, 51, 4518-4528.
61. T.A.Clarke and L.A.Waskell. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin.Drug Metabolism and Disposition(2003),31(1),53-59, DOI: 10.1124/dmd.31.1.53.
62. A.Algaier,J.A.Jakubowski,F.Asai and I.von Kügelgen. Interaction of the active metabolite of prasugrel, R-138727, with cysteine 97 and cysteine 175 of the human P2Y12 receptor. Journal of Thrombosis and Haemostasis (2008),6(11), 1908-1914 , DOI: 10.1111/j.1538-7836.2008.03136.x.
63. P.M.Dansette,J.Libraire,G.Bertho and D.Mansuy. Metabolic oxidative cleavage of thioesters: evidence for the formation of sulfenic acid intermediates in the bioactivation of the antithrombotic prodrugs ticlopidine and clopidogrel. Chemical Research in Toxicology (2009),22, 369-373.